Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

31. März 2023 07:00 ET | Quelle: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Anti-CD3 mAb Research for the Treatment of Alzheimer’s Disease to be Presented by Dr. Howard Weiner at the International Conference on Alzheimer’s and Parkinson’s Disease and Related Neurological Disorders Conference in Sweden

Data shows reduction of microglia activation and improvement in behavior in rodent model of Alzheimer’s disease (AD)Modulation of neuroinflammation may be synergistic to existing treatments in AD NEW...
08. März 2021 16:05 ET | Quelle: Prothena Corporation plc

Prothena to Hold Investor Webcast to Review Three Oral Presentations from AD/PD 2021

Superior profile of novel anti-tau antibody PRX005 supports advancement for the potential treatment of Alzheimer’s diseaseNew analyses of prasinezumab continue to support potential disease modifying...
24. Februar 2021 16:05 ET | Quelle: Prothena Corporation plc

Prothena Announces Promising New Preclinical and Clinical Data from its Neurodegenerative Programs Selected for Oral Presentations at AD/PD 2021

Robust preclinical data support the benefit of PRX005, a novel anti-tau antibody, for the potential treatment Alzheimer’s diseaseNew pre-specified exploratory subgroup analyses and new digital...